A highly durable RNAi therapeutic inhibitor of PCSK9

New England Journal of Medicine

Volumn 376, Issue 18, 2017, Pages e38-

  Koh, Kwang K ^a  

^a Gachon University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCLISIRAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE 9; LOW DENSITY LIPOPROTEIN RECEPTOR; SERINE PROTEINASE;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DRUG MECHANISM; GENE; GENETIC ANALYSIS; GENETIC VARIABILITY; GLUCOSE INTOLERANCE; HMGCR GENE; LETTER; PCSK9 GENE; PRIORITY JOURNAL; RISK ASSESSMENT; RNAI THERAPEUTICS; GENETICS; HUMAN; METABOLISM; RNA INTERFERENCE;

CHOLESTEROL, LDL; HUMANS; PROPROTEIN CONVERTASES; RECEPTORS, LDL; RNA INTERFERENCE; RNAI THERAPEUTICS; SERINE ENDOPEPTIDASES;

EID: 85019042609     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med 2016; 375: 2144-53.
2. Lotta LA, Sharp SJ, Burgess S, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-Analysis. JAMA 2016; 316: 1383-91.
3. Lim S, Sakuma I, Quon MJ, Koh KK. Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality. Int J Cardiol 2013; 167: 1696-702.